Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: Influenced by the HER2- and Topoisomerase IIα-status of the primary tumor?

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 8, 2005, Pages 539-546

  Schindlbeck, C ^a   Janni, W ^a   Shabani, N ^a   Kornmeier, A ^a   Rack, B ^a   Rjosk, D ^a   Gerber, B ^b   Braun, S ^c   Sommer, H ^a   Friese, K ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

Anthracyclin; Bone marrow; Breast cancer; Chemotherapy; Her2; Isolated tumor cells; Minimal residual disease; Prognosis; Topoisomerase

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; ISOENZYME; METHOTREXATE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CELL ISOLATION; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR CELL;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BONE MARROW; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 24044526879     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-005-0683-y     Document Type: Article

References (32)

1. Bartlett J, Mallon E, Cooke T (2003) The clinical evaluation of HER-2 status: which test to use? J Pathol 199:411-417
2. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K, (2000a) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18:80-86
3. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000b) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533
4. Braun S, Vogl FD, Schlimok G, Diel IJ, Janni W, Gerber B, Gebauer G, Coombes RC, Pierga J-Y, Naume B, Pantel K (2003) Pooled analysis of prognostic impact of bone marrow micrometastasis: 10-year survival of 4199 breast cancer patients. Presentation, 26th Annual San Antonio Breast Cancer Symposium
5. Chearskul S, Onreabroi S, Churintrapun M, Semprasert N, Bhothisuwan K (2001) Immunohistochemical study of c-erbB-2 expression in primary breast cancer. Asian Pac J Allergy Immunol 19:197-205
6. Coleman RE (2003) Current and future status of adjuvant therapy for breast cancer. Cancer 97:880-886
7. Coon JS, Marcus E, Gupta-Burt S, Seelig S, Jacobson K, Chen S, Renta V, Fronda G, Preisler HD (2002) Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 8:1061-1067
8. Cortes F, Pastor N, Mateos S, Dominguez I (2003) Roles of DNA topoisomerases in chromosome segregation and mitosis. Mutat Res 543:59-66
9. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS (2000) Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol 13:542-547
10. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ (2002) HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116
11. Durbecq V, Di Leo A, Cardoso F, Rouas G, Leroy JY, Piccart M, Larsimont D (2003) Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 77:199-204
12. Hellemans P, van Dam PA, Geyskens M, van Oosterom AT, Buytaert P, Van Marck E (1995) Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol 48:147-150
13. Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, Hantschmann P, Sommer H, Pantel K, Braun S (2001) The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 92:46-53
14. Jarvinen TA, Liu ET (2003) HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 78:299-311
15. Jarvinen TA, Kononen J, Pelto-Huikko M, Isola J (1996) Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am J Pathol 148:2073-2082
16. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142-150
17. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S, Isola J (2000) Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156:839-847
18. Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML (2000) HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 5:199-207
19. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T, Senn HJ (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600-2608
20. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U (2001) Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19:354-363
21. MacGrogan G, Rudolph P, Mascarel II, Mauriac L, Durand M, Avril A, Dilhuydy JM, Robert J, Mathoulin-Pelissier S, Picot V, Floquet A, Sierankowski G, Coindre JM (2003) DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer. Br J Cancer 89:666-671
22. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424
23. Park K, Kim J, Lim S, Han S (2003) Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 39:631-634
24. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651-3664
25. Riou G, Mathieu MC, Barrois M, Le Bihan ML, Ahomadegbe JC, Benard J, Le MG (2001) c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein overexpression in operable breast-cancer patients. Int J Cancer 95:266-270
26. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413-428
27. Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM, Parwaresch R (1999) Prognostic significance of Ki-67 and topoisomerase II-alpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat 55:61-71
28. Schindlbeck C, Janni W, Shabani N, Rack B, Gerber B, Schmitt M, Harbeck N, Sommer H, Braun S, Friese K (2004) Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow. Breast Cancer Res Treat 87:65-74
29. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
30. Wang JC (2002) Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 3:430-440
31. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B (2004) Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 10:5342-5348
32. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61[Suppl 2]:1